Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp110 | Calcium and Bone 2 | ECE2019

Denosumab in post-liver transplantation osteoporosis: preliminary data on the effects on bone mineral density and turnover markers

Zavatta Guido , Vandi Giulia , Di Dalmazi Guido , Repaci Andrea , Ravaioli Matteo , Cescon Matteo , Morelli Maria Cristina , Pagotto Uberto , Altieri Paola

Introduction: Several risk factors are involved in post-liver transplantation osteoporosis. Immunosuppressive agents, glucocorticoids, decreased renal function associated with secondary hyperparathyroidism and immobilization are the main determinants of fragility fractures in this population. Denosumab is highly effective in increasing bone mineral density (BMD) and preventing fragility fractures. However, the efficacy of denosumab in liver transplantation osteoporosis has nev...

ea0081rc13.5 | Rapid Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Skeletal muscle mass in patients with adrenal incidentaloma

Colombin Giacomo , Vara Giulio , Fanelli Flaminia , Magagnoli Matteo , Tucci Lorenzo , Coscia Kimberly , Mosconi Cristina , Pagotto Uberto , Vicennati Valentina , Di Dalmazi Guido

Background and aim: The relationship between sarcopenia and overt cortisol excess as in Cushing’s syndrome is well-known. However, only a few studies investigated the relationship between autonomous cortisol secretion (ACS) in adrenal incidentalomas and skeletal muscle mass. The aims of our study were to analyze the skeletal muscle mass in patients with adrenal incidentalomas and to investigate the correlations with hormonal data.Methods: We enrolle...

ea0073oc6.6 | Oral Communications 6: Calcium and Bone | ECE2021

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

Schwarz Peter , Rejnmark Lars , Rubin Mishaela , Vokes Tamara J. , Clarke Bart L. , Ahmed Intekhab , Palermo Andrea , Marcocci Claudio , Pagotto Cristina , Eriksen Erik , Mourya Sanchita , Markova Denka , Pihl Susanne , Shu Aimee , Beckert Michael , Khan Aliya

BackgroundHypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiologic levels of calcitriol, promoting independence from Ca and active vitamin D supplements and normalization of QoL. TransCon PTH is an investigational long-acting p...